P53 AND C-ERBB-2 ALTERATIONS IN IN-SITU AND INVASIVE DUCTAL BREAST CARCINOMAS - A GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS

  • Authors:
    • A MARCHETTI
    • F BUTTITTA
    • S PELLEGRINI
    • D CAMPANI
    • D CECCHETTI
    • M BISTOCCHI
  • View Affiliations

  • Published online on: August 1, 1995     https://doi.org/10.3892/ijo.7.2.343
  • Pages: 343-347
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

p53 mutations, c-erbB-2 amplifications and expression of the related proteins were evaluated in a panel of ductal breast carcinomas selected on the basis of their invasive component. The tumors comprised: 8 ductal carcinomas in situ (DCIS); 8 carcinomas with a minimal (less than 20%) invasive component, hereafter referred to as DCIC (<20%); 13 carcinomas with 20%-50% invasiveness, DCIC (20-50%), and 48 infiltrating carcinomas with more than 50% invasive component, DCIC (>50%). Tumors were further subdivided into large pleomorphic cell type or small regular cell type. A strong association was present between p53 gene mutations and p53 protein overexpression (p<0.001) as well as between amplification of the c-erbB-2 gene and expression of its protein product (p=0.006). p53 aberrations (gene mutation and/or protein overexpression) were observed in 1 (12%) of 8 DCIS, 1 (11%) of 9 DCIC (<20%), 3 (23%) of 13 DCIC (20%-50%), and 13 (28%) of 47 DCIC (>50%). Amplification and/or overexpression of c-erbB-2 were found in 30 (39%) of the 77 breast carcinomas analyzed and were more frequent in DCIC (<20%) and in DCIC (20%-50%) (56% and 46% respectively) than in DCIS or DCIC (>50%) (12% and 38% respectively). Irrespective of the presence of invasion, tumors with p53 or c-erbB-2 alterations showed more frequently large cells with pleomorphic nuclei, (for p53, p=0.027; for c-erbB-2, p=0.014). Our data suggest that p53 and c-erbB-2 alerations may occur in the earliest recognized phase of breast cancer and may be important in the evolution of small cell to large cell mammary carcinoma during tumor progression.

Related Articles

Journal Cover

August 1995
Volume 7 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
MARCHETTI A, BUTTITTA F, PELLEGRINI S, CAMPANI D, CECCHETTI D and BISTOCCHI M: P53 AND C-ERBB-2 ALTERATIONS IN IN-SITU AND INVASIVE DUCTAL BREAST CARCINOMAS - A GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS. Int J Oncol 7: 343-347, 1995
APA
MARCHETTI, A., BUTTITTA, F., PELLEGRINI, S., CAMPANI, D., CECCHETTI, D., & BISTOCCHI, M. (1995). P53 AND C-ERBB-2 ALTERATIONS IN IN-SITU AND INVASIVE DUCTAL BREAST CARCINOMAS - A GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS. International Journal of Oncology, 7, 343-347. https://doi.org/10.3892/ijo.7.2.343
MLA
MARCHETTI, A., BUTTITTA, F., PELLEGRINI, S., CAMPANI, D., CECCHETTI, D., BISTOCCHI, M."P53 AND C-ERBB-2 ALTERATIONS IN IN-SITU AND INVASIVE DUCTAL BREAST CARCINOMAS - A GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS". International Journal of Oncology 7.2 (1995): 343-347.
Chicago
MARCHETTI, A., BUTTITTA, F., PELLEGRINI, S., CAMPANI, D., CECCHETTI, D., BISTOCCHI, M."P53 AND C-ERBB-2 ALTERATIONS IN IN-SITU AND INVASIVE DUCTAL BREAST CARCINOMAS - A GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS". International Journal of Oncology 7, no. 2 (1995): 343-347. https://doi.org/10.3892/ijo.7.2.343